Anadys Pharma assumed with a Neutral from Underperform at Wedbush
Wedbush assumed coverage of Anadys Pharma and upgraded the stock to Neutral from Underperform. The firm has a $3 target on shares. :theflyonthewall.com
News For ANDS From The Last 14 Days
Check below for free stories on ANDS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
